Blog section

HIV Reservoirs and Eradication Research Community Blog

New anti-HIV Gene Therapy Trials Launched – Testing Moves Forward

Alain Lafeuillade
Alain Lafeuillade has not set their biography yet
User is currently offline
Posted on Thursday, 19 January 2012
in Clinical Aspects

New anti-HIV gene therapy trials launched is the recent news regarding a promising potential treatment for HIV. This new round of trials is the Phase 2 clinical round after this treatment passed Phase 1. Two new phase 2 clinical studies are now being launched, according to the maker of the treatment, Sangamo BioSciences, Inc. These new trials are entitled SB-728-1101 and SB-728-902, Cohort 5. The plan is for this treatment to pan out as a functional cure for HIV/AIDS. The research process is ongoing.

New anti-HIV gene therapy trials launched is the recent news regarding a promising potential treatment for HIV. This new round of trials is the Phase 2 clinical round after this treatment passed Phase 1. Two new phase 2 clinical studies are now being launched, according to the maker of the treatment, Sangamo BioSciences, Inc. These new trials are entitled SB-728-1101 and SB-728-902, Cohort 5. The plan is for this treatment to pan out as a functional cure for HIV/AIDS. The research process is ongoing.

This approach of Sangamo’s that has sparked new anti-HIV gene therapy trials launched is called ZFP Therapeutic, or SB-728-T. It generates T cells that resist HIV infection with ZFN, or zinc finger nuclease technology. HIV enters cells using a co-receptor called CCR5, and ZFN is designed to disrupt its DNA sequence encoding permanently. T cells are a type of white blood cell that is part of the immune system, and are also called T lymphocytes and thymocytes. The Phase 1 clinical trials were entitled SB-728-T.

These new anti-HIV gene therapy trials launched to test out two different approaches to make more engrafted T cells that have both gene copies of CCR5 biallelically modified in subjects infected with HIV and treated with ZFP Therapeutic. The SB-728-902, Cohort 5 study is intended to find out how ZFP Therapeutic affects the HIV viral load in naturally heterozygous subjects concerning the CCR5 delta-32 gene mutation. This means that out of their two CCR5 gene copies, one is normal and one has the mutation. The SB-728-1101 study aims to investigate a conditioning pretreatment intended to increase the number of T cells that are engrafted and biallelically modified in HIV-infected subjects lacking the CCR5 delta-32 mutation.

New anti-HIV gene therapy trials launched has happened ahead of schedule, according to Sangamo BioSciences, Inc., or SGMO on NASDAQ. The Phase 1 trials data showed a relationship that is statistically significant between a reduced HIV viral load in HIV-infected subjects during interrupted anti-retroviral therapy and circulating quantity of T cells with doubly modified CCR5 genes. These new Phase 3 clinical studies are intended to investigate the potential of ZFP Therapeutic for significantly treating HIV further. ZFP Therapeutic at this stage of research is a potential therapy among others for treating effectively and even functionally curing HIV/AIDS that shows some early promise. The research on this and other promising potential treatments will be exciting to watch in the years ahead.

Press Release: http://investor.sangamo.com/releasedetail.cfm?ReleaseID=637760

Related Articles:
Rate this blog entry
Alain Lafeuillade has not set their biography yet

TRACKBACK

TRACKBACK URL FOR BLOG ENTRY

COMMENTS

PLEASE LOGIN TO SUBMIT COMMENT